Fair is Fair; But Science is Science
This article was originally published in RPM Report
Theravance’s proposed new indication for Vibativ is not the first drug to fail because of evolving regulatory standards. It may, however, have provoked the clearest and most formal articulation of FDA’s views on the limits of “fairness” regarding drug development commitments when it comes to approval decisions.
You may also be interested in...
Accelerating Antibiotic Drug Development: FDA Goes Beyond GAIN
FDA is sending a message to industry and Congress of its ongoing work to help companies with antibiotic drug development– beyond the requirements of the FDA Safety and Innovation Act.
“Feasibility” Counts at FDA: Different Approach in Antibiotics
Venture capitalists and other investors in drug development often howl about FDA policy changes that they view as crippling innovation in certain classes. They may not think FDA listens, but clearly the agency does. FDA just doesn’t always agree.
Data Integrity and Antibiotic Clinical Trials: FDA, Industry Try Systemic Therapy
FDA's push to encourage development of new antibiotics requires getting past data integrity issues in the class. The agency's workshop on antibacterial clinical trials revealed a range of efforts aimed at better Good Clinical Practices compliance - and those efforts can just as easily be applied to other drug classes